State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China.
The First People's Hospital of Tianmen, Tianmen 431700, China.
Int J Cardiol. 2022 Mar 15;351:1-7. doi: 10.1016/j.ijcard.2022.01.003. Epub 2022 Jan 5.
To evaluate the prognostic influence of the presence of right ventricular myocardial infarction (RVMI) on patients with inferior ST-segment elevation myocardial infarction (STEMI) in the contemporary reperfusion era.
9308 patients with inferior STEMI were included from the prospective, nationwide, multicenter China Acute Myocardial Infarction Registry, including 1745 (18.75%) patients with RVMI and 7563 (81.25%) patients without RVMI. The primary outcome was two-year all-cause mortality. The secondary outcome was major adverse cardiac and cerebrovascular event (MACCE) defined as a composite of all-cause mortality, recurrent MI, revascularization, stroke, and major bleeding.
After two-year follow up, there were no significant differences between inferior STEMI patients with or without RVMI in all-cause mortality (12.0% vs 11.3%; adjusted HR: 1.05; 95% CI: 0.90 to 1.24; P = 0.5103). Inferior STEMI with RVMI was associated with higher risk of MACCE (25.6% vs 22.0%; adjusted HR: 1.17; 95% CI: 1.05 to 1.31; P = 0.0038), revascularization (10.3% vs 8.1%; adjusted HR: 1.23; 95% CI: 1.03 to 1.48; P = 0.0218), and major bleeding (4.6% vs 2.7%; adjusted HR: 1.56; 95% CI: 1.18 to 2.07; P = 0.0019). Primary percutaneous coronary intervention (PCI) and thrombolysis were independent predictors to decrease all-cause mortality. For patients who received timely reperfusion, RVMI involvement did not increase all-cause mortality, whereas for those who did not undergo reperfusion, RVMI increased all-cause mortality (20.3% vs 15.7%; HR: 1.34; 95% CI: 1.10 to 1.63).
RVMI did not increase all-cause mortality for inferior STEMI patients in contemporary reperfusion era, whereas the risk was increased for patients with no reperfusion treatment.
评估右心室心肌梗死(RVMI)对当代再灌注时代下下壁 ST 段抬高型心肌梗死(STEMI)患者预后的影响。
9308 例下壁 STEMI 患者纳入前瞻性、全国性、多中心的中国急性心肌梗死注册研究,其中 1745 例(18.75%)患者合并 RVMI,7563 例(81.25%)患者未合并 RVMI。主要结局为 2 年全因死亡率。次要结局为主要不良心脑血管事件(MACCE),定义为全因死亡率、再发心肌梗死、血运重建、卒中和大出血的复合终点。
2 年随访后,下壁 STEMI 患者无论是否合并 RVMI,全因死亡率均无显著差异(12.0% vs. 11.3%;调整 HR:1.05;95%CI:0.90 至 1.24;P=0.5103)。合并 RVMI 的下壁 STEMI 患者 MACCE 风险更高(25.6% vs. 22.0%;调整 HR:1.17;95%CI:1.05 至 1.31;P=0.0038)、血运重建(10.3% vs. 8.1%;调整 HR:1.23;95%CI:1.03 至 1.48;P=0.0218)和大出血(4.6% vs. 2.7%;调整 HR:1.56;95%CI:1.18 至 2.07;P=0.0019)的风险更高。直接经皮冠状动脉介入治疗(PCI)和溶栓是降低全因死亡率的独立预测因素。对于接受及时再灌注的患者,RVMI 并不增加全因死亡率,而对于未接受再灌注治疗的患者,RVMI 会增加全因死亡率(20.3% vs. 15.7%;HR:1.34;95%CI:1.10 至 1.63)。
在当代再灌注时代,RVMI 并未增加下壁 STEMI 患者的全因死亡率,而对于未接受再灌注治疗的患者,其风险增加。